Company news
Voyager Therapeutics, Inc. (NASDAQ:VYGR) news
Every Voyager Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Voyager Technologies, Inc. Announces Proposed Convertible Senior Notes Offering
September 22, 2026
Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026
July 13, 2026
Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026
June 29, 2026
Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference
June 11, 2026
Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease
June 1, 2026
Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026
May 13, 2026
Voyager Reports First Quarter 2026 Financial and Operating Results
May 7, 2026
Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer’s Disease
April 27, 2026
Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
March 9, 2026
Voyager to Present at Upcoming Investor Conferences
February 9, 2026
Voyager Reports Third Quarter 2025 Financial and Operating Results
November 10, 2025
Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia
November 10, 2025
Voyager Reports Second Quarter 2025 Financial and Operating Results
August 6, 2025
Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach
July 16, 2025
Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
June 10, 2025
Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication
May 15, 2025
Voyager Reports First Quarter 2025 Financial and Operating Results
May 6, 2025
Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting
April 28, 2025
Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025
March 31, 2025
Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
March 11, 2025
Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast
March 4, 2025
Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer’s Disease
March 3, 2025
Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences
February 25, 2025
Voyager Provides Update on SOD1 ALS Gene Therapy Program
February 11, 2025
Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease
November 20, 2024
Voyager Reports Third Quarter 2024 Financial and Operating Results
November 12, 2024
Voyager Therapeutics Announces Third Quarter 2024 Conference Call and Webcast
November 5, 2024
Voyager Advances Collaboration with Neurocrine; Third Gene Therapy Development Candidate Selected
September 16, 2024
Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14
September 5, 2024
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 29, 2024
Voyager Therapeutics Reports Second Quarter 2024 Financial and Operating Results
August 6, 2024
Voyager Therapeutics Announces Second Quarter 2024 Conference Call and Webcast
July 30, 2024
Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer
June 13, 2024
Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease
May 16, 2024
Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results
May 13, 2024
Voyager Therapeutics Presents Data for Second-Generation, TRACER™-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting
May 8, 2024
Voyager Therapeutics Announces First Quarter 2024 Conference Call and Webcast
May 6, 2024
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
April 16, 2024
Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer
March 13, 2024
Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
February 28, 2024
Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich’s Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
February 26, 2024
Voyager Therapeutics Announces Fourth Quarter 2023 Conference Call and Webcast
February 21, 2024
Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer’s Disease and Advances Program into Late Research
February 20, 2024
Voyager Therapeutics Announces Proposed Public Offering
January 4, 2024
Voyager Therapeutics Announces Pricing of Public Offering
January 4, 2024
Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies
January 2, 2024
Voyager Therapeutics Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program
December 6, 2023
Voyager Therapeutics Reports Third Quarter 2023 Financial and Operating Results
November 6, 2023
Voyager Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
October 30, 2023
Voyager Therapeutics Announces Appointment of Beth Shafer as Chief Business Officer
August 7, 2023